Ignite Creation Date:
2024-05-06 @ 3:31 PM
Last Modification Date:
2024-10-26 @ 1:50 PM
Study NCT ID:
NCT04652258
Status:
UNKNOWN
Last Update Posted:
2021-10-07
First Post:
2020-11-26
Brief Title:
Pyrexia Management Using an IL-6 Antibody in BRAF Melanoma Patients Treated With Dabrafenib Trametinib - Immunotherapy
Sponsor:
University of Zurich
Organization:
University of Zurich
Study Overview
Official Title:
A Phase II Open Label Single Arm Single Center Study to Evaluate Pyrexia Management With or Without Any Other Cytokine Release Symptoms Using Tocilizumab an Humanized Monoclonal Antibody Against the Interleukin - 6 Receptor in BRAF Melanoma Patients Treated With Dabrafenib Trametinib - Immunotherapy
Status:
UNKNOWN
Status Verified Date:
2021-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Nov IIT- Pyrex
Brief Summary:
The study examines the development of fever after administration of Actemra tocilizumab in patients who have fever and other cytokine release symptoms headache nausea palpitations low blood pressure due to cancer therapy Tafinlar dabrafenib Mekinist trametinib - immunotherapy The goal of the study is to better understand the side effects and to find an effective therapy against them
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None